Xvivo Perfusion AB
STO:XVIVO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
256.5
539
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Xvivo Perfusion AB
Xvivo Perfusion AB
Income from Continuing Operations
Xvivo Perfusion AB
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Income from Continuing Operations
kr204.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
77%
|
CAGR 10-Years
41%
|
|
|
O
|
OssDsign AB
STO:OSSD
|
Income from Continuing Operations
-kr130.5m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
D
|
Doxa AB
STO:DOXA
|
Income from Continuing Operations
-kr208.2m
|
CAGR 3-Years
-145%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-25%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Income from Continuing Operations
-kr138.4m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Income from Continuing Operations
€972k
|
CAGR 3-Years
-75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Income from Continuing Operations
-kr1.9m
|
CAGR 3-Years
54%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Xvivo Perfusion AB
Glance View
Xvivo Perfusion AB is a medical technology company. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 92 full-time employees. The company went IPO on 2012-10-08. The firm operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The firm markets its products in Europe, Asia, Middle East, and North & South America.
See Also
What is Xvivo Perfusion AB's Income from Continuing Operations?
Income from Continuing Operations
204.3m
SEK
Based on the financial report for Sep 30, 2024, Xvivo Perfusion AB's Income from Continuing Operations amounts to 204.3m SEK.
What is Xvivo Perfusion AB's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
41%
Over the last year, the Income from Continuing Operations growth was 748%.
You don't have any saved screeners yet
